Doxoccord LP Caution For Usage

Incompatibilities: This medicinal product must not be mixed with other medicinal products except those mentioned in Special precautions for disposal and other handling as follows.
Special precautions for disposal and other handling: Do not use material that shows evidence of precipitation or any other particulate matter.
Caution must be exercised in handling Doxoccord LP solution. The use of gloves is required. If Doxoccord LP comes into contact with skin or mucosa, wash immediately and thoroughly with soap and water. Doxoccord LP must be handled and disposed of in a manner consistent with that of other anticancer medicinal products in accordance with local requirements.
Determine the dose of Doxoccord LP to be administered (based upon the recommended dose and the patient's body surface area). Take the appropriate volume of Doxoccord LP up into a sterile syringe. Aseptic technique must be strictly observed since no preservative or bacteriostatic agent is present in Doxoccord LP. The appropriate dose of Doxoccord LP must be diluted in 5% (50 mg/mL) glucose solution for infusion prior to administration. For doses <90 mg, dilute Doxoccord LP in 250 mL, and for doses ≥90 mg, dilute Doxoccord LP in 500 mL. This can be infused over 60 or 90 minutes as detailed in Dosage & Administration.
The use of any diluent other than 5% (50 mg/mL) glucose solution for infusion, or the presence of any bacteriostatic agent such as benzyl alcohol may cause precipitation of Doxorubicin pegylated liposomal.
It is recommended that the Doxorubicin pegylated liposomal infusion line be connected through the side port of an intravenous infusion of 5% (50 mg/mL) glucose. Infusion may be given through a peripheral vein. Do not use with in-line filters.